



PB 45 of 2026

National Health (June 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026

I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.

Dated 29 April 2026

REBECCA RICHARDSON

Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

1 Name

- (1) This instrument is the *National Health (June 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026*.
- (2) This instrument may also be cited as PB 45 of 2026.

2 Commencement

This instrument commences on 1 June 2026.

3 Authority

This instrument is made under sections 99ACB and 99ACD of the *National Health Act 1953*.

4 Definitions

Note: A number of expressions used in this instrument are defined in Part VII the Act.

In this instrument:

Act means the *National Health Act 1953*.

Reduction day refers to 1 June 2026.

5 Brands of pharmaceutical item (combination items) not subject to a price reduction

- (1) I determine under paragraph 99ACD(7A)(a) of the Act that the agreed price of the brand of pharmaceutical item specified in item 1 in the table in Part 1 of Schedule 1 that comes into force on the reduction day is to be equal to the approved ex-manufacturer price, on the day before the determination day, of the listed brands of the existing item.

6 Brands of pharmaceutical item (not combination items) not subject to a price reduction

- (1) I determine under paragraph 99ACB(6A)(a) of the Act that the agreed price of the brand of pharmaceutical item specified in item 1 in the table in Part 1 of Schedule 2 that comes into force on the reduction day is to be equal to the approved ex-manufacturer price, on the day before the determination day, of the listed brands of the existing item.

Schedule 1 Brands of pharmaceutical item (combination items) not subject to a price reduction

Part 1

Column 1	Column 2			
Item	Brand of pharmaceutical item			
	Drug	Form	Manner of administration	Brand
1	Drospirenone with ethinylestradiol	Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets	Oral	Mila

Schedule 2 Brands of pharmaceutical item (not combination items) not subject to a price reduction

Part 1

Column 1	Column 2			
Item	Brand of pharmaceutical item			
	Drug	Form	Manner of administration	Brand
1	Febuxostat	Tablet 80 mg	Oral	Febexic